Delcath Systems, Inc. Announces Promising Results from Independent Study of Repeated Hepatic Chemosaturation for Liver Tumors Page 1

Delcath Systems, Inc. (Nasdaq: DCTH) (“Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by researchers at the University Hospital Leipzig, Germany, in the European Society for Medical Oncology journal Gastrointestinal Oncology. The study, entitled “Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation,” highlights the efficacy and safety of repeated chemosaturation treatments using Delcath’s CHEMOSAT Hepatic Delivery System.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240826877468/en/